Why the study?
Do new oral anticoagulants reduce stroke and systemic embolism compared to warfarin in patients with atrial fibrillation?
Do new oral anticoagulants reduce stroke and systemic embolism compared to warfarin in patients with atrial fibrillation?
New oral anticoagulants are promising alternatives to warfarin for stroke prevention in atrial fibrillation, with high-dose regimens offering better efficacy and low-dose regimens offering better safety regarding hemorrhagic events.
No takes yet. Share an insight, caveat, or question.
High-dose NOACs improve efficacy while low-dose reduce ICH and mortality in AF; extends evidence guiding dose selection over warfarin.
Jia et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: